tiprankstipranks
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
US Market

Diamedica Therapeutics (DMAC) Income Statement

449 Followers

Diamedica Therapeutics Income Statement

Last quarter (Q4 2023), Diamedica Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Diamedica Therapeutics's net income was $-5.16M. See Diamedica Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 10.22M$ 21.27M$ 14.00M$ 13.65M$ 12.49M$ 10.74M
Operating Income
$ -10.22M$ -21.27M$ -14.00M$ -13.65M$ -12.49M$ -10.74M
Net Non Operating Interest Income Expense
------
Other Income Expense
$ -1.93M$ -1.93M$ -353.00K$ -82.00K$ 229.00K$ 119.00K
Pretax Income
$ -19.34M$ -19.34M$ -13.65M$ -13.56M$ -12.27M$ -10.62M
Tax Provision
$ 43.00K$ 43.00K$ 28.00K$ 28.00K$ 27.00K$ 31.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -8.34M$ -19.38M$ -13.68M$ -13.59M$ -12.29M$ -10.65M
Basic EPS
$ -0.61$ -0.60$ -0.52$ -0.65$ -0.78$ -0.89
Diluted EPS
$ -0.61$ -0.60$ -0.52$ -0.65$ -0.78$ -0.89
Basic Average Shares
$ 130.27M$ 32.57M$ 26.44M$ 20.77M$ 15.68M$ 11.99M
Diluted Average Shares
$ 130.27M$ 32.57M$ 26.44M$ 20.77M$ 15.68M$ 11.99M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 10.22M$ 21.27M$ 14.00M$ 13.65M$ 12.49M$ 10.74M
Net Income From Continuing And Discontinued Operation
$ -19.38M$ -19.38M$ -13.68M$ -13.59M$ -12.29M$ -10.65M
Normalized Income
$ -11.13M$ -15.29M$ -10.79M-$ -12.29M$ -10.65M
Interest Expense
------
EBIT
$ -19.34M$ -19.34M$ -13.65M$ -13.56M$ -12.49M$ -10.74M
EBITDA
$ -19.31M$ -19.31M$ -13.62M$ -13.54M$ -12.47M$ -10.72M
Currency in USD

Diamedica Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis